You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma
SBC: L2 DIAGNOSTICS LLC Topic: 102DESCRIPTION provided by applicant Hepatocellular carcinoma HCC is the most prevalent cancer in human population and will lead to over deaths in the United States this year alone However the molecular mechanisms driving hepatocellular carcinoma HCC growth and metastasis remain elusive and there is a huge unmet medical need to find new therapeutic targets We performed an unbiased ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic inhibition of P. aeruginosa nitrogen respiration in chronic infection
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION provided by applicant The goal of this STTR is to identify novel small molecule compounds targeting the nitrogen respiration pathway of Pseudomonas aeruginosa This pathway is crucial to the pathogenesis of P aeruginosa in vivo but has not yet been exploited for antimicrobial drug discovery There is a clear need for new treatments to combat P aeruginosa infections Antibiotic re ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Topical application of heterologous protein-expressing Staphylococcus epidermidis for potential therapeutic treatment of skin diseases
SBC: Azitra Inc. Topic: NIAIDPROJECT SUMMARY Current treatment options for a number of skin diseases generally aim for symptomatic relief and fail to address underlying pathophysiological changes leading to skin disease In the case of genetic mutations that cause loss of function mutations supplementation of the missing protein is a viable approach to treatment However delivery of functional protein to the target keratino ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
